Comprehensive Dermatologic Drug Therapy Comprehensive Dermatologic Drug Therapy

Comprehensive Dermatologic Drug Therapy

    • $134.99
    • $134.99

Publisher Description

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you’re likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today's full spectrum of topical, intralesional, and systemic drugs. You’ll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor.
Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions. Covers the best uses for new biologic therapeutics. Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors. Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols. Features a highly detailed, disease-specific index, as well as purchase information for major drugs. Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book.

GENRE
Professional & Technical
RELEASED
2019
December 14
LANGUAGE
EN
English
LENGTH
858
Pages
PUBLISHER
Elsevier Health Sciences
SELLER
Elsevier Inc
SIZE
88.8
MB

More Books Like This

Microbiology for Surgical Infections Microbiology for Surgical Infections
2014
Handbook of Drug-Nutrient Interactions Handbook of Drug-Nutrient Interactions
2011
Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring
2012
Inflammatory Bowel Disease Inflammatory Bowel Disease
2022